Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

Kotmayer, Lili and László, Tamás and Mikala, Gábor and Kiss, Richárd and Lévay, Luca and Hegyi, Lajos and Gróf, Stefánia and Nagy, Tibor and Barna, Gábor and Farkas, Péter and Weisinger, Júlia and Nagy, Zsolt and Balogh, Alexandra and Masszi, Tamás and Demeter, Judit and Sulák, Adrienn and Kohl, Zoltán and Alizadeh, Hussain and Egyed, Miklós and Pettendi, Piroska and Gergely, Lajos and Plander, Márk and Pauker, Zsolt and Masszi, András and Matolcsy, András and Szász, Róbert and Bödör, Csaba and Alpár, Donát (2023) Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (6). No-5802. ISSN 1661-6596 (print); 1422-0067 (online)

Preview

Text Kotmayer_IJMS_2023.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and D103Y, sensitive (10−4) screening for the most common BCL2 mutations G101V and D103Y was performed in 67 R/R CLL patients during venetoclax single-agent or venetoclax–rituximab combination therapy. With a median follow-up time of 23 months, BCL2 G101V and D103Y were detected in 10.4% (7/67) and 11.9% (8/67) of the cases, respectively, with four patients harboring both resistance mutations. Ten out of eleven patients carrying BCL2 G101V and/or D103Y experienced relapse during the follow-up period, representing 43.5% of the cases (10/23) showing clinical signs of disease progression. All BCL2 G101V or D103Y variants were detected in patients receiving venetoclax as a continuous single-agent treatment while these mutations were not observed during or after fixed-duration venetoclax therapy. Targeted ultra-deep sequencing of BCL2 uncovered three additional variants in four patient samples obtained at relapse, suggesting convergent evolution and implying a cooperating role of BCL2 mutations in driving venetoclax resistance. This cohort is the largest R/R CLL patient population reported to date in which BCL2 resistance mutations were investigated. Our study demonstrates the feasibility and clinical value of sensitive screening for BCL2 resistance mutations in R/R CLL.

Actions (login required)

Edit Item